Labiotech.eu

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 26 Oct 2015

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

Biotech financing beats record over record since beginning of 2014. Financing has never been as high in Europe (though of course, we know this has always been the case for the US). Just look at Neil Woodford, famous british investor who raised €1.1Bn for its fund and injected it in many companies like Immuncore (2nd biggest VC round […]

October 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 24 Oct 2015

What Happened this Week? Ultimate Cancer Review, Biofuels, Microalgae

Monday: Monster €167M NASDAQ-IPO coming for Swiss Antibiotic Biotech Basilea Tuesday: The Ultimate Review on how Biotech Changed Cancer Treatment Wednesday: “CAR-T / TCR Deserves to have a lot of Money because the Data is Very Exciting” Thursday: Aquanos Algae: Israeli Start-up fixes the Global Sustainability issue in Recycling Sewage Water Friday: #Sorry: The World-leading Oncology Company […]

October 24, 2015 - 1 minutemin - By Philip Hemme

News and Trends 23 Oct 2015

#Sorry: The World-leading Oncology Company fails in Phase III

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts… Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to […]

October 23, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 23 Oct 2015

Biotech of the week: Genenta Biosciences, a Novel Gene Therapies from Italy

This week we depart from East Germany and head south, through both Liechtenstein and Switzerland to the northern region of Italy, Lombardy. Here we arrive in Italy’s second largest city, Milan. This city is the center of fashion, Italian cuisine and is home to Da Vinci’s, ‘The Last Supper’ however, it is also home […]

October 23, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Lyon’s Erytech (France) is a clinical biopharma working on improving its red blood cell transported drug, targeting cancers such as acute lymphocytic leukemia (ALL) and pancreatic adenocarcinoma. Now phase I/II trials for its GRASPA therapy have demonstrated good efficacy and safety. Circulating asparagine is needed by cancer cells to grow and proliferate. Erytech’s platform uses […]

October 22, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

Aquanos Algae: Israeli Start-up fixes the Global Sustainability issue in Recycling Sewage Water

Aquanos has the solution to expensive and energy intensive waste-water treatment. Having revamped the pre-existing Microalgae technique for sewage remediation to be far more efficient, the Gemini project also generates biomass products and is being trialed on a Northern Israeli kibbutz, with negotiable projections for use in the developing world. Man, we cannot get enough of […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 21 Oct 2015

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

Gritstone Pharmaceuticals is a US start-up which will focus on R&D of its new CAR-T cancer therapy technique: tumor-specific neo-antigen (TSNA). An impressive financial syndicate is backing its launch this month, having achieved a £102M series A pot for their lung cancer research. This cash is a clear indication that this start-up has the 3 […]

October 21, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 21 Oct 2015

The SuperBones; Polymeric Smart Coating Strategy for Titanium Implants

Uppsala University (Sweden) in joint collaboration with Neutron-Scattering experts at the Institute of Laue-Langevin in Grenoble (France) will change the medical world of implants. A new growth-stimulating ‘gel’ will therefore help the body adopt such implants as its own – as man and machine merge! Welding artificial hip joints or making dental implants from titanium […]

October 21, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 Oct 2015

Scaling-up Biofuels: The Challenges of Giant Bioreactors

Global Bioenergies from France is building a proto-plant for Isobutene production in Germany, with partnerships with car manufacturer Audi. Now their plant will receive a 5,000 Litre fermentation tank, after overcoming the challenging process of scaling-up second generation biofuel production. Global Bioenergies’ return to first generation biofuel production has already been discussed as a bit […]

October 20, 2015 - 3 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

What Happened this Week? Ultimate Cancer Review, Biofuels, Microalgae

#Sorry: The World-leading Oncology Company fails in Phase III

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Biotech of the week: Genenta Biosciences, a Novel Gene Therapies from Italy

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Aquanos Algae: Israeli Start-up fixes the Global Sustainability issue in Recycling Sewage Water

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

The SuperBones; Polymeric Smart Coating Strategy for Titanium Implants

Scaling-up Biofuels: The Challenges of Giant Bioreactors

Subscribe to our newsletter to get the latest biotech news!